Verastem Oncology Announces New CEO Appointment and $250M Securities Offering
Verastem Oncology (NASDAQ: VSTM) announced the appointment of Michael Bailey as its new president and CEO, effective January 1, 2027. The company also priced a securities offering expected to raise up to $250 million in proceeds. Following these announcements, Verastem's shares rose approximately 20% in premarket trading on Wednesday. The transition marks the next phase of leadership for the biopharmaceutical firm as it continues its focus on developing therapies for patients with cancer. The new CEO appointment and capital raise are expected to support ongoing research efforts and operational growth, potentially strengthening investor confidence ahead of 2027.
Topics: Biopharmaceuticals Leadership Change
Read the full article at Seeking Alpha
Part of the story Verastem Oncology Announces $250M Securities Offering (2 articles)